The paracrine role of tumour-derived mIL-4 on tumour-associated endothelium

International Journal of Cancer

Volumn 72, Issue 4, 1997, Pages 664-672

  Saleh, Mary ^a   Davis, Ian D ^b   Wilks, Andrew F ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER IMMUNOLOGY; ENDOTHELIUM CELL; GLIOMA; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN NEOPLASMS; CELL DIVISION; CLONING, MOLECULAR; DNA, COMPLEMENTARY; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM; EOSINOPHILS; FEMALE; GENETIC VECTORS; GLIOMA; INTERLEUKIN-4; LYMPHOKINES; MALE; MICE; MICE, NUDE; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TETRACYCLINE; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030741044     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970807)72:4<664::AID-IJC19>3.0.CO;2-B     Document Type: Article

References (30)

1. BUBENIK, J., SIMOVA, J. and JANDLOVA, T., Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol. Lett., 23, 287-292 (1990).
2. DAVIS, I.D., TRBUTLEIN, H.R., FREIDRICH, K. and BURGESS, A.W., A potent human interleukin-4 antagonist stimulates the proliferation of murine cells expressing the human interleukin-4 binding chain. Growth. Factors. 12, 69-83 (1995).
3. DE MICCO, C., Immunology of central nervous system tumours. J. Neuroimmunol., 25, 93-108 (1989).
4. DE VRIES, C., ESCOBEDO, J.A., UENO, H., HOUCK, K., FERRARA, N. and WILLIAMS, L.T., The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 255, 989-991 (1992).
5. FOLKMAN, J., Anti-ansiogenesis: new concepts of therapy of solid tumors. Ann. Surg., 175, 409-416 (1972).
6. FOLKMAN, J., Tumour ansiogenesis: a possible control point in tumour growth. Ann. Int. Med., 82, 96-100 (1975).
7. FONG, G., ROSSANT, J., GERTSENSTEIN, M. and BREITMAN, M.L., Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (Loud.). 376, 66-70 (1995).
8. GOLUMBEK, P.T., LAZENBY, A.J., LEVITSKY, H.I., JAFFEE, L.M., KARASUYAMA, H., BAKER, M. and PARDOLL, D.M., Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science, 254, 713-716 (1991).
9. GOSSEN, M. and BUJARD, H., Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. nat. Acad. Sci. (Wash.), 89, 5547-5551 (1992).
10. HOWARD, M., FARRAR, J., HILFIKER, M., JOHNSON, B., TAKATSU, K., HAMAOKA, T. and PAUL, W.E., Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J. exp. Med., 155, 914-923 (1982).
11. KIM, K.J., LI, B., WINER, J., ARMANINI, M., GILLETT, N., PHILLIPS, H.S. and FERRARA, N., Inhibition of vascular endothelial growth factor-induced ansiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362, 841-844 (1993).
12. KRUGER-KRASAGAKES, S., LI, W., RICHTER, G., DIAMANTSTEIN, T. and BLANKENSTEIN, T., Eosinophils infiltrating interleukin-5 gene-transfected tumors do not suppress tumor growth. Europ. J. Immunol., 23, 992-995 (1993).
13. LEE, F., YOKOTA, T., OTSUKA, T., MEYERSON, P., VILLARET, D., COFFMAN, R., MOSMANN, T., RENNICK, D., ROEHM, N., SMITH, C., ZLOTNIK, A. and ARAI, K., Isolation and characterisation of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities. Proc. nat. Acad. Sci. (Wash.), 83, 2061-2065 (1986).
14. LEUNG, D.W., CACHIANES, G., KUANG, W.J., GOEDDEL, D.V. and FERRARA, N., Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246, 1306-1309 (1989).
15. MILLAUER, B., SHAWVER, L.K., PLATE, K.L., RISAU, W. and ULLRICH, A., Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (Lond.), 367, 576-579 (1994).
16. MILLAUER, B., WIZIGMANN-VOOS, S., SCHNURCH, H., MARTINEZ, R., MOLLER, N.P.H., RISAU, W. and ULLRICH, A., High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72, 835-846 ( 1993).
17. O'REILLY, M., HOLMGREN, L., OMEN, C. and FOLKMAN, J., Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature (Med.), 2, 689-692 (1996).
18. OELRICHS, R.B., REID, H.H., BERNARD, O., ZIEMIECKI, A. and WILKS, A.F., NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepitheium is expressed in endothelial cells of the developing embryo. Oncogene, 8, 11-18 (1993).
19. PLATE, K.H., BREIER, G., WEICH, H.A. and RISAU, W., Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (Land.), 359, 845-848 ( 1992).
20. SALEH, M., STACKER, S.A. and WILKS, A.F., Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor (VEGF) sequence. Cancer Res., 56, 393-401 (1996a).
21. SALEH, M., VASILOPOULOS, K., STYLLI, S.S., KAYE, A.H. and WILKS, A.F., The expression of antisense vascular endothelial growth factor (VEGF) sequences inhibit intracranial glioma growth in vivo by suppressing tumour angiogenesis. J. clin. Neurosci., 3, 366-372 (19966).
22. SCHLEIMER, R.P., STERBINSKY, S.A., KAISER, J., BICKEL, C.A., KLUNK, D.A., TOMIOKA, K., NEWMAN, W., LUSCINSKAS, F.W., GIMBRONE, M.A.J., MCINTYRE, B.W. and BOCHNER, B.S., IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. J. Immunol., 148, 1086-1092 (1992).
23. SHALABY, F., ROSSANT, J., YAMAGUCHI, T.P., GERTSENSTEIN, M., WU, X., BREITMAN, M.L. and SCHUH, A.C., Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (Loud.), 376, 62-66 (1995).
24. SHWEIKI, D., ITIN, A., SOFFER, D. and KFSHET, E., Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.), 359, 843-845 (1992).
25. TEPPER, R.I., COFFMAN, R.L. and LEDER, P., An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science, 257, 548-551 (1992).
26. TEPPER, R.I., PATTENGALE, P.K. and LEDER, P., Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell, 57, 503-512 (1989).
27. TERMAN, B.I., DOUGHER-VERMAZEN, M., CARRION, M.E., DIMITROV, D., ARMFLLINO, D.C., GOSPODAROWICZ, D. and BOHLEN, P., Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. biophys. Res. Comm., 187, 1579-1586 (1993).
28. THORNHILL, M.H., KYAN-AUNG, U. and HASKARD, D.O., IL-4 increases human endothelial cell adhesiveness for T cells but not for neutrophils. J. Immunol., 144, 3060-3065 ( 1990).
29. WATANABE, Y., KURIBAYASHI, K., MIYATAKE, S., NISHIHARA, K., NAKAYAMA, E., TANIYAMA, T. and SAKATA, T., Exogenous expression of mouse Interferon gamma in mouse neuroblastoma C1300 cells results in reduced tumourigenicity by augmented anti-tumour immunity. Proc. nat. Acad. Sci. (Wash.), 86, 9456-9460 (1989).
30. YU, J.S., WEI, M.X., CHIOCCA, E.A., MARTUZA, R.L. and TEPPER, R.I., Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res., 53, 3125-3128 (1993).